W
#Novartis #Pharmaceuticals #Oncology
www.wsj.com
Novartis to Buy Breast-Cancer Drug From Synnovation for Up to $3 Billion
Novartis is paying $2 billion upfront and up to $1 billion subject to targets to acquire Pikavation Therapeutics. fabrice coffrini/Agence France-Presse/Getty Images
Novartis NOVN -1.
#Diabetes #Generics #Pharmaceuticals
ca.finance.yahoo.com
Novo Nordisk patent expiry opens door to cheaper weight-loss drugs in India
HYDERABAD, March 19 (Reuters) - India's market for diabetes and weight-loss drugs is set for a shake-up as Danish drugmaker Novo Nordisk's patent on semaglutide expires this week, triggering a wave of cheaper generics from local drugmakers and worries about uneven oversight in an overcrowded market.
#Pharmaceuticals #DrugPricing #HealthcarePolicy
www.cnbc.com
Drug pricing, patent losses and deals: Here's what pharma execs see ahead in the industry
Big pharma is grappling with the impact of new drug pricing deals with President Donald Trump and roughly $300 billion in potential lost revenue from patent expirations of blockbuster drugs.
#Healthcare #PharmacyServices #CommunityHealth
www.beckershospitalreview.com
New Research Shows Increased Urgency to Improve Community Pharmacy Access and Reduce Gaps in Service
VytlOne Releases 2nd Annual Healthcare Leader Report -- Reviving Access, Reclaiming Revenue: Strengthening Hospitals and Communities Through Strategic Pharmacy Expansion
AMARILLO, Texas, Nov.
#WeightManagement #ObesityTreatment #PharmaceuticalInnovation
www.nasdaq.com
Will NVO's Wegovy Pill Approval for Obesity be a Game Changer in 2026?
Last month, Novo Nordisk NVO announced the FDA approval of the Wegovy pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain weight reduction in the long term, and to reduce the risk of major adverse cardiovascular (CV) events.
#Hypertension #HeartHealth #Pharmaceuticals
www.benzinga.com
Idorsia's JERAYGO (aprocitentan) approved in Canada for the treatment of resistant hypertension
Enter your email to get Benzinga's ultimate morning update: The PreMarket Activity NewsletterIdorsia receives approval from Health Canada for JERAYGO™ (aprocitentan) as the first and only endothelin receptor antagonist (ERA) for the treatment of resistant hypertension.
#AI #Oncology #Pharmaceuticals
www.benzinga.com
Insilico Medicine Announce US$888 Million Multi-Year Collaboration with Servier for Drug Discovery and Development in Oncology
Enter your email to get Benzinga's ultimate morning update: The PreMarket Activity NewsletterInsilico Medicine achieved an R&D collaboration with Servier valued at up to US$888 million, focused on discovering and developing innovative oncology therapies, by combining Insilico's AI-driven drug discovery platforms with Servier's global expertise in cancer drug development.
#Pharmaceuticals #ClinicalTrials #EndocrineDiseases
www.benzinga.com
Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia - Crinetics Pharmaceuticals (NASDAQ:CRNX)
SAN DIEGO, Jan.
